Darunavir CAS 206361-99-1 Anti-HIV Purity ≥99.0% API High Purity HIV Protease Inhibitor

Chemical Name: Darunavir  CAS: 206361-99-1 Appearance: White or Off-White Crystalline Powder Purity: ≥99.0% HIV-1 Protease Inhibitor Anti-HIV API High Quality, Commercial Production Inquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer Supply Darunavir Related Products: Darunavir CAS 206361-99-1 Darunavir Ethanolate CAS 635728-49-3 (2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98737-29-2 (2R,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98760-08-8 (3S)-3-(tert-Butoxycarbonyl)amino-1-Chloro-4-Phenyl-2-Butanone CAS 102123-74-0
Item Specifications
Appearance White or Off-White Crystalline Powder
Identification MS/HNMR HPLC
Solubility Soluble in DMSO, Slightly Soluble in Water
Melting Point 74.0~76.0℃
Identification 1H NMR
Purity / Analysis Method ≥99.0% (HPLC)
Related Substances
Max Single Impurity ≤0.30%
Total Impurities ≤1.0%
Residual Solvents Ethanol ≤0.30%
Loss on Drying ≤0.50%
Residue on Ignition ≤0.10%
Heavy Metals ≤20ppm
Arsenic ≤1.5ppm
Test Standard Enterprise Standard
Usage Darunavir (CAS 206361-99-1) HIV-1 Protease Inhibitor Anti-HIV 

Description:

Specifications:

Package & Storage:

Chemical Name Darunavir
Synonyms TMC114; UIC-94017
CAS Number 206361-99-1
CAT Number RF-API68
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C27H37N3O7S
Molecular Weight 547.66
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

Darunavir (brand name Prezista, formerly known as TMC114) is a protease inhibitor medication used to treat HIV infection. Darunavir is an OARAC recommended treatment option for treatment-naive and treatment-experienced adults and adolescents. Darunavir is a new kind of non peptide anti retroviral protease inhibitors in AIDS therapy. It is first developed by the Johnson pharmaceutical Iceland branch, Tibotec. It is of the highest bioavailability in the 6 protease inhibitors (saquinavir, ritonavirvir, indinavir, naphthalene nelfinavir, amprenavir and ABT378/r). It acts by blocking the formation of new and mature virus particles from the surface of the infected host cells and inhibiting the virus's protease. When the product is used for a long time, it usually can reduce the HIV virus vector in blood, increase the count of CD4 cells, reduce the chance of HIV infection, improve the quality of life and prolong life. It is suitable for adults who are infected with the HIV virus but have no effect on the use of existing antiretroviral drugs. The drug must be combined with the use of low doses of ritonavir or other antiretroviral agents, in order to improve the efficacy. The antiviral activity in vitro can be evaluated by being against acute and chronic infected lymphocytes and lymphocytes in peripheral blood.

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours